Motilal Oswal's research report on Procter and Gamble Hygiene and Health care
PGHH reported high single-digit sales growth in 1QFY24 (ending in June), surpassing our initial double-digit growth expectations. PAT up 36% YoY driven by an increase in volume growth, a favorable product price-mix, and enhanced productivity. GP margin has been expanded 230bps, while operating margin expanded by 450 bps owing to the benefit of operating leverage. Ad-spends mounted sequentially to 13.5% of sales from 6.3% (albeit, declined 140bp YoY) during the quarter.
Outlook
The company continues to grow with strong product portfolio of sanitary napkins and healthcare business, superior consumer communications and stream of product innovations. With the challenging valuations of ~64.9xFY24E EPS/~54.4xFY25E EPS led us to maintain our Neutral rating on the stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Procter & Gamble Hygiene & Health Care - 31 - 10-2023 - moti
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
